🔎 Trials Near Me

Почетна › Рак дојке › Masachuset › Boston

Kliničke studije za Рак дојке u gradu Boston, MA

110 studija za Рак дојке traži učesnike na lokacijama u gradu Boston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Тражи се учесникФаза 3
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Тражи се учесникФаза 3
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05894239

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Тражи се учесникФаза 1
  • Dana-Farber Cancer Institute, Boston
Узраст 12 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05372640

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Тражи се учесникФаза 1/2
  • Research Facility, Boston
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT06590857

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Тражи се учесникФаза 3
  • Massachusetts General Hospital Cancer Center ( Site 0091), Boston
  • Dana Farber Cancer Institute ( Site 0090), Boston
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700

Prospective Screening for Breast Cancer-related Lymphedema

Тражи се учесникОпсервациона студија
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT01521741

Screening For BCRL In Targeted Therapy For Breast Cancer

Тражи се учесникОпсервациона студија
  • Massachusetts General Hospital, Boston
Узраст од 18 до 80 · Жене · Ажурирано 10. 11. 2026. · NCT05142800

The COMPASSION Study

Тражи се учесник
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06507930

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Тражи се учесникФаза 1
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07029399

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Тражи се учесникФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06324357

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Тражи се учесник
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07214532

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Тражи се учесникФаза 1/2
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT05315700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Тражи се учесникФаза 3
  • Tufts Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Тражи се учесникФаза 3
  • Mass General Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336

E-Mindfulness Approaches for Living After Breast Cancer

Тражи се учесникФаза 3
  • Tufts Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Тражи се учесникФаза 2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213791

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07114601

Distance-Based Exercise to Preserve Function and Prevent Disability

Тражи се учесник
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07059884

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute - Oncology Department, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Тражи се учесникФаза 3
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Жене · Ажурирано 3. 11. 2026. · NCT07524855

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07578571

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Тражи се учесникФаза 3
  • Dana-Farber Cancer Institute, Boston
Узраст 60 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06377852

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Тражи се учесникФаза 1
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Тражи се учесникФаза 2
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07102381

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07109726

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Тражи се учесникФаза 3
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT05646862

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07100106

Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

Тражи се учесникФаза 1
  • Massachusetts General Brigham, Boston
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07807345

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Тражи се учесникФаза 1
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07383506

The Cancer of the Pancreas Screening-5 CAPS5)Study

Тражи се учесникФаза 3
  • Dana Farber Cancer Center, Harvard University, Boston
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT02000089

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Тражи се учесникФаза 1/2
  • Dana-Farber Cancer Institute ( Site 0050), Boston
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT06686394

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Тражи се учесникФаза 3
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Тражи се учесникФаза 1
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07137416

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Тражи се учесникФаза 2
  • Dana Farber Cancer Institute, Boston
Узраст 70 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT04305834

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06239194

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Тражи се учесникФаза 1
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Тражи се учесникФаза 3
  • Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037), Boston
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06312176

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Тражи се учесникФаза 1/2
  • Research Site, Boston
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT05123482

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Тражи се учесникФаза 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06993844

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Тражи се учесникФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT05386108

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Тражи се учесникФаза 3
  • Massachusetts General Hospital Cancer Center, Boston
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06757634

TRUDI: TDXD+Durva in HER2+/Low IBC

Тражи се учесникФаза 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Жене · Ажурирано 9. 10. 2026. · NCT05795101

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Тражи се учесникФаза 1/2
  • Research Site, Boston
Узраст од 18 до 130 · Оба пола · Ажурирано 5. 10. 2026. · NCT05417594

A Study of PHST001 in Advanced Solid Tumors

Тражи се учесникФаза 1
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06840886

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06784193

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Insitute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06625775

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07701941

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Тражи се учесникФаза 2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06369285

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Тражи се учесникФаза 1
  • Research Site, Boston
  • Research Site, Boston
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT05877599

IKS014 in Advanced Solid Tumors That Express HER2

Тражи се учесникФаза 1
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT05872295

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Тражи се учесникФаза 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT04899908

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06253871

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Тражи се учесникФаза 1
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06488378

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Тражи се учесникФаза 1/2
  • Dana Farber Cancer Institute, Boston
Узраст од 18 до 100 · Оба пола · Ажурирано 27. 8. 2026. · NCT06726148

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2026. · NCT06533826

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2026. · NCT07222215

Optimizing Surgical Decisions in Young Adults With Breast Cancer

Тражи се учесник
  • Dana-Farber Cancer Institute, Boston
Узраст од 18 до 44 · Жене · Ажурирано 19. 8. 2026. · NCT06275126

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Тражи се учесникФаза 2
  • Dana Farber Cancer Institute, Boston
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 19. 8. 2026. · NCT04893109

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 12. 8. 2026. · NCT05304962

Supporting Health Including Endocrine Treatment for Long Duration

Тражи се учесник
  • Dana-Farber Cancer Institute, Boston
Узраст од 18 до 49 · Жене · Ажурирано 10. 8. 2026. · NCT07482384

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Тражи се учесникФаза 2/3
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Тражи се учесникФаза 3
  • Massachusetts General Hospital Cancer Center, Boston
Узраст од 18 до 100 · Оба пола · Ажурирано 6. 8. 2026. · NCT05232916

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 6. 8. 2026. · NCT06176261

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 6. 8. 2026. · NCT06439693

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

Тражи се учесникЗдраве особе су добродошле
  • Massachusetts General Hospital, Boston
Узраст од 45 до 74 · Жене · Ажурирано 31. 7. 2026. · NCT05625659

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
Узраст од 18 до 100 · Оба пола · Ажурирано 29. 7. 2026. · NCT06562192

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute, Boston
Узраст од 18 до 55 · Жене · Ажурирано 27. 7. 2026. · NCT06184750

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Тражи се учесникФаза 2
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 8 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05503797

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Тражи се учесник
  • Dana Farber Cancer Institute, Boston
Узраст 65 и старији · Жене · Ажурирано 17. 7. 2026. · NCT05535192

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

Тражи се учесникЗдраве особе су добродошле
  • Massachusetts General Hospital, Boston
Узраст 60 и старији · Жене · Ажурирано 16. 7. 2026. · NCT02290834

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT05768139

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

Тражи се учесникОпсервациона студија
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 30. 6. 2026. · NCT07675967

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Тражи се учесникФаза 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Тражи се учесникФаза 2
  • GSK Investigational Site, Boston
Узраст 18 и старији · Оба пола · Ажурирано 24. 6. 2026. · NCT04641247

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Жене · Ажурирано 22. 6. 2026. · NCT05573126

Scalp Cooling in MBC

Тражи се учесникФаза 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 18. 6. 2026. · NCT04986579

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Тражи се учесникФаза 3
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 12. 6. 2026. · NCT05950945

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Тражи се учесникФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT07198724

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Тражи се учесникФаза 1
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 8. 6. 2026. · NCT04890613

Oncoplastic Surgery Outcomes Database

Тражи се учесникОпсервациона студија
  • Tufts Medical Center, Boston
Узраст 18 и старији · Жене · Ажурирано 27. 5. 2026. · NCT07597837

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

Тражи се учесникОпсервациона студија
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston
Узраст од 18 до 80 · Жене · Ажурирано 22. 5. 2026. · NCT06551220

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Тражи се учесникФаза 2
  • Massachusetts General Hospital Cancer Center, Boston
Узраст 18 и старији · Жене · Ажурирано 6. 5. 2026. · NCT03990896

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Тражи се учесникФаза 2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 4. 5. 2026. · NCT04434040

VS-6766+Abema+Fulv in Met HR+/HER- BC

Тражи се учесникФаза 1/2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institite, Boston
Узраст 18 и старији · Оба пола · Ажурирано 30. 4. 2026. · NCT05608252

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Тражи се учесникФаза 2
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 29. 4. 2026. · NCT04468061

Remote Monitoring and Symptom Management Digital Application

Тражи се учесник
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 28. 4. 2026. · NCT07553572

Exercise in Metastatic Breast Cancer: EMBody

Тражи се учесник
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 27. 4. 2026. · NCT05468034

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Тражи се учесникФаза 1
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Жене · Ажурирано 22. 4. 2026. · NCT05683418

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

Тражи се учесникФаза 2Здраве особе су добродошле
  • Dana-Farber Cancer Institute, Boston
Узраст 80 и старији · Жене · Ажурирано 22. 4. 2026. · NCT07123649

SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

Тражи се учесник
  • Beth Israel Deaconess Medical Center, Boston
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 7. 4. 2026. · NCT06896474

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Тражи се учесникФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 6. 4. 2026. · NCT05785741

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Тражи се учесникФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 1. 4. 2026. · NCT05735080

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Тражи се учесникОпсервациона студија
  • Eastern Cooperative Oncology Group, Boston
Сви узрасти · Оба пола · Ажурирано 27. 3. 2026. · NCT02610413

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Тражи се учесникОпсервациона студија
  • Eastern Cooperative Oncology Group, Boston
Сви узрасти · Оба пола · Ажурирано 27. 3. 2026. · NCT02610439

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Тражи се учесникФаза 1/2
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 27. 3. 2026. · NCT06395519

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Тражи се учесникОпсервациона студија
  • Eastern Cooperative Oncology Group, Boston
Сви узрасти · Оба пола · Ажурирано 27. 3. 2026. · NCT02610426

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Тражи се учесникФаза 2
  • Dana Farber Cancer Institute (Data Collection Only), Boston
Узраст 18 и старији · Оба пола · Ажурирано 25. 2. 2026. · NCT06099769

Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction

Тражи се учесник
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 22. 1. 2026. · NCT07209436

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Тражи се учесникФаза 4
  • Massachussets General Hospital, Boston
Узраст од 18 до 64 · Оба пола · Ажурирано 22. 1. 2026. · NCT04373564

Refining Local-Regional Therapy for IBC

Тражи се учесник
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Жене · Ажурирано 29. 12. 2025. · NCT04636710

Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

Тражи се учесник
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 18. 11. 2025. · NCT06795529

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Тражи се учесникФаза 2
  • Massachusetts General Hospital, Boston
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2025. · NCT04553770

Strength After Breast Cancer

Тражи се учесник
  • MGH Institute of Health Professions, Boston
Узраст 18 и старији · Жене · Ажурирано 20. 10. 2025. · NCT06052488

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Тражи се учесникФаза 1/2
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2025. · NCT05941507

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Тражи се учесникФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2025. · NCT05216432

Comprehensive Outcomes for After Cancer Health

Тражи се учесникЗдраве особе су добродошле
  • Dana Farber Cancer Institute, Boston
Узраст 18 и старији · Оба пола · Ажурирано 11. 12. 2024. · NCT05349227

Studije za Рак дојке u drugim gradovima

Ostale studije u gradu Boston

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.